|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Witjes JA, Bruins HM, Cathomas R, Compérat
EM, Cowan NC, Gakis G, Hernández V, Espinós EL, Lorch A, Neuzillet
Y, et al: European association of urology guidelines on
muscle-invasive and metastatic bladder cancer: Summary of the 2020
guidelines. Eur Urol. 79:82–104. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Babjuk M, Burger M, Capoun O, Cohen D,
Compérat EM, Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A,
Mostafid AH, et al: European association of urology guidelines on
non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ).
Eur Urol. 81:75–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Oliveira MC, Caires HR, Oliveira MJ,
Fraga A, Vasconcelos MH and Ribeiro R: Urinary biomarkers in
bladder cancer: Where do we stand and potential role of
extracellular vesicles. Cancers (Basel). 12:14002020. View Article : Google Scholar
|
|
5
|
Allory Y, Beukers W, Sagrera A, Flández M,
Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I,
Vermeij M, et al: Telomerase reverse transcriptase promoter
mutations in bladder cancer: High frequency across stages,
detection in urine, and lack of association with outcome. Eur Urol.
65:360–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moonen PM, Kiemeney LA and Witjes JA:
Urinary NMP22 bladderchek test in the diagnosis of superficial
bladder cancer. Eur Urol. 48:951–956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lam EWF, Brosens JJ, Gomes AR and Koo CY:
Forkhead box proteins: Tuning forks for transcriptional harmony.
Nat Rev Cancer. 13:482–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Katoh M, Igarashi M, Fukuda H, Nakagama H
and Katoh M: Cancer genetics and genomics of human FOX family
genes. Cancer Lett. 328:198–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamashita H, Amponsa VO, Warrick JI, Zheng
Z, Clark PE, Raman JD, Wu XR, Mendelsohn C and DeGraff DJ: On a FOX
hunt: Functions of FOX transcriptional regulators in bladder
cancer. Nat Rev Urol. 14:98–106. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
11
|
Mahlapuu M, Ormestad M, Enerback S and
Carlsson P: The forkhead transcription factor Foxf1 is required for
differentiation of extra-embryonic and lateral plate mesoderm.
Development. 128:155–166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paulsson J and Micke P: Prognostic
relevance of cancer-associated fibroblasts in human cancer. Semin
Cancer Biol. 25:61–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sturtzel C, Lipnik K, Hofer-Warbinek R,
Testori J, Ebner B, Seigner J, Qiu P, Bilban M, Jandrositz A,
Preisegger KH, et al: FOXF1 mediates endothelial progenitor
functions and regulates vascular sprouting. Front Bioeng
Biotechnol. 6:762018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ren X, Ustiyan V, Pradhan A, Cai Y,
Havrilak JA, Bolte CS, Shannon JM, Kalin TV and Kalinichenko VV:
FOXF1 transcription factor is required for formation of embryonic
vasculature by regulating VEGF signaling in endothelial cells. Circ
Res. 115:709–720. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu Y and Hu C: Bioinformatic analysis of
the prognostic value and potential regulatory network of FOXF1 in
papillary thyroid cancer. Biofactors. 45:902–911. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao ZG, Wang DQ, Hu DF, Li YS and Liu SH:
Decreased FOXF1 promotes hepatocellular carcinoma tumorigenesis,
invasion, and stemness and is associated with poor clinical
outcome. Onco Targets Ther. 9:1743–1752. 2016.PubMed/NCBI
|
|
17
|
Herrera-Merchan A, Cuadros M, Rodriguez
MI, Rodriguez S, Torres R, Estecio M, Coira IF, Loidi C, Saiz M,
Carmona-Saez P and Medina PP: The value of lncRNA FENDRR and FOXF1
as a prognostic factor for survival of lung adenocarcinoma.
Oncotarget. 11:1172–1185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Magers MJ, Lopez-Beltran A, Montironi R,
Williamson SR, Kaimakliotis HZ and Cheng L: Staging of bladder
cancer. Histopathology. 74:112–134. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Davis S and Meltzer PS: GEOquery: A bridge
between the gene expression omnibus (GEO) and bioconductor.
Bioinformatics. 23:1846–1847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y,
Zhou R, Qiu W, Huang N, Sun L, et al: IOBR: Multi-omics
immuno-oncology biological research to decode tumor
microenvironment and signatures. Front Immunol. 12:6879752021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang V, Qin Y, Wang J, Wang X, Place RF,
Lin G, Lue TF and Li LC: RNAa is conserved in mammalian cells. PLoS
One. 5:e88482010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hoffman-Censits JH, Grivas P, Van Der
Heijden MS, Dreicer R, Loriot Y, Retz M, Vogelzang NJ, Perez-Gracia
JL, Rezazadeh A, Bracarda S, et al: IMvigor 210, a phase II trial
of atezolizumab (MPDL3280A) in platinum-treated locally advanced or
metastatic urothelial carcinoma (mUC). J Clin Oncol. 34 (Suppl
2):S3552016. View Article : Google Scholar
|
|
24
|
Hrudka J, Prouzová Z, Mydlíková K,
Jedličková K, Holešta M, Whitley A and Havlůj L: FOXF1 as an
immunohistochemical marker of hilar cholangiocarcinoma or
metastatic pancreatic ductal adenocarcinoma. Single institution
experience. Pathol Oncol Res. 27:16097562021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lo PK, Lee JS, Chen H, Reisman D, Berger
FG and Sukumar S: Cytoplasmic mislocalization of overexpressed
FOXF1 is associated with the malignancy and metastasis of
colorectal adenocarcinomas. Exp Mol Pathol. 94:262–269. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lo PK, Lee JS, Liang X, Han L, Mori T,
Fackler MJ, Sadik H, Argani P, Pandita TK and Sukumar S: Epigenetic
inactivation of the potential tumor suppressor gene FOXF1 in breast
cancer. Cancer Res. 70:6047–6058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu CY, Chan CH, Dubey NK, Wei HJ, Lu JH,
Chang CC, Cheng HC, Ou KL and Deng WP: Highly expressed FOXF1
inhibit non-small-cell lung cancer growth via inducing tumor
suppressor and G1-phase cell-cycle arrest. Int J Mol Sci.
21:32272020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang S, Xiao Z, Hong Z, Jiao H, Zhu S,
Zhao Y, Bi J, Qiu J, Zhang D, Yan J, et al: FOXF1 promotes
angiogenesis and accelerates bevacizumab resistance in colorectal
cancer by transcriptionally activating VEGFA. Cancer Lett.
439:78–90. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang S, Yan S, Zhu S, Zhao Y, Yan J, Xiao
Z, Bi J, Qiu J, Zhang D, Hong Z, et al: FOXF1 induces
epithelial-mesenchymal transition in colorectal cancer metastasis
by transcriptionally activating SNAI1. Neoplasia. 20:996–1007.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Creagh EM, Conroy H and Martin SJ:
Caspase-activation pathways in apoptosis and immunity. Immunol Rev.
193:10–21. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van Opdenbosch N and Lamkanfi M: Caspases
in cell death, inflammation, and disease. Immunity. 50:1352–1364.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi Y: Mechanisms of caspase activation
and inhibition during apoptosis. Mol Cell. 9:459–470. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vince JE, De Nardo D, Gao W, Vince AJ,
Hall C, McArthur K, Simpson D, Vijayaraj S, Lindqvist LM, Bouillet
P, et al: The mitochondrial apoptotic effectors BAX/BAK activate
caspase-3 and −7 to trigger NLRP3 inflammasome and caspase-8 driven
IL-1β activation. Cell Rep. 25:2339–2353.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ford CA, Petrova S, Pound JD, Voss JJ,
Melville L, Paterson M, Farnworth SL, Gallimore AM, Cuff S, Wheadon
H, et al: Oncogenic properties of apoptotic tumor cells in
aggressive B cell lymphoma. Curr Biol. 25:577–588. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morana O, Wood W and Gregory CD: The
apoptosis paradox in cancer. Int J Mol Sci. 23:113282022.
View Article : Google Scholar
|
|
37
|
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF,
O'Sullivan B, He Z, Peng Y, Tan AC, et al: Caspase 3-mediated
stimulation of tumor cell repopulation during cancer radiotherapy.
Nat Med. 17:860–866. 2011. View Article : Google Scholar : PubMed/NCBI
|
